On 20 June 2011, Floyd J. granted a temporary restraining order preventing restraining Teva UK Limited (and two distribution companies, “Phoenix” and “AAH”) from advertising, offering for sale, selling or supplying its generic atorvastatin pending full hearing of the Warner-Lambert’s application for an interim injunction, listed for 11 July 2011. Warner-Lambert (a subsidiary of Pfizer…

The Hargreaves Review, or to refer to it by its official title, “A Review of Intellectual Property and Growth” by Professor Ian Hargreaves, was commissioned by the UK coalition government in 2010 to report on various issues pertaining to intellectual property with a particular focus on copyright, particularly in the online environment, as well as…

The Court of Appeal overturned a decision of the High Court and held that the act of replacing Shutz’s bottles in Shutz’s outer protective cages with Werit’s bottles constituted ’ making’  products protected by Shutz’s patent, which encompassed both the bottle and the cage. Click here for the full text of this case. A full summary…

As previously discussed, the English Court of Appeal has clearly stated its support for judicial collaboration facilitating de facto harmonisation of patent law in Europe (Grimme Landmaschinenfabrik GmbH v Scott [2010] EWCA Civ 1110). However, in a recent decision in the English Patents Court (Lundbeck v Norpharma and Infosint [2011] EWHC 907), Floyd J. expressed…

In a judgment dated 17 March 2011 reported at [2011] EWHC 583 (Pat), the English High Court has upheld certain claims of two patents (deriving from the same ultimate parent application) for the formulation of Ethinylestradiol (“EE”) and Drospirenone (“DSP”) used in contraception. The patents in issue belonged to Bayer Schering Pharma AG. The Hungarian…

In the recent case of Schütz v Werit, the Court of Appeal examined the boundary between repair and making under the English implementation of Article 25 of the Community Patent Convention. The claimants’ patent in question was for intermediate bulk containers (IBCs), in particular IBCs comprising two parts: a cage and a large plastic container…

If a party decides to participate in another party’s challenge to a patent so it may share in the benefits of a victory, it may well be ordered to share the costs burden of losing. Actavis was therefore ordered to pay half of Eli Lilly’s costs of successfully defending the revocation actions brought by Dr…